A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

NCT02073227 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers

Interventions

DRUG: Canagliflozin, 300 mg
DRUG: Metformin XR, 500 mg
DRUG: CANA/MET XR FDC, Formulation 1, 150 mg/1,000 mg
DRUG: CANA/MET XR FDC, Formulation 2, 150 mg/1,000 mg

Sponsor

Janssen Research & Development, LLC